Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?

被引：0
|
作者：
Alkan, Ali [2 ]
Sahin, Ugur [2 ]
Altundag, Kadri [1 ]
机构：
[1] Hacettepe Univ, Dept Med Oncol, Inst Oncol, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Sch Med, Dept Internal Med, TR-06100 Ankara, Turkey
来源：
MEDICAL ONCOLOGY | 2010年 / 27卷 / 04期
关键词：
Paclitaxel; Docetaxel; Gemcitabin; Taxane; Anthracycline;
D O I：
10.1007/s12032-009-9322-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1430 / 1430
页数：1
相关论文
共 50 条
  • [21] Adjuvant and neoadjuvant treatment of breast cancer
    Gianni, L
    Valagussa, P
    Zambetti, M
    Moliterni, A
    Capri, G
    Bonadonna, G
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 13 - 29
  • [22] Adjuvant and neoadjuvant therapy for breast cancer
    Shien, Tadahiko
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (03) : 225 - 229
  • [23] Outcome of Treatment After Locoregional Radiation, Neoadjuvant and Adjuvant Chemotherapy for Breast Cancer
    Anie, H. N. Ayettey
    Yarney, J.
    Sanuade, O.
    Awasthi, S.
    Ndanu, T. Akuetteh
    Parekh, A.
    Aidoo, C. A.
    Dadzie, M. A.
    Vanderpuye, V.
    Yamoah, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E418 - E418
  • [24] Adjuvant and neoadjuvant chemotherapy of breast cancer
    Untch, M.
    Thomssen, C.
    ONKOLOGE, 2015, 21 (03): : 231 - 238
  • [25] Neoadjuvant and Adjuvant Therapies for Breast Cancer
    Apuri, Susmitha
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (10) : 638 - 642
  • [26] Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
    Vaid, Ashok K.
    Khurana, Aseem
    Sharma, Devender
    Gautam, Dheeraj
    Wadhwa, Jyoti
    Agarwal, Rajiv
    Kaur, Kanchan
    Arora, Jyoti
    Gupta, Kush
    WORLD JOURNAL OF ONCOLOGY, 2020, 11 (03) : 106 - 111
  • [27] Does neoadjuvant versus adjuvant systemic treatment improve outcomes in breast cancer?
    Roukos, DH
    Kappas, AM
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (07): : 342 - 343
  • [28] Does neoadjuvant versus adjuvant systemic treatment improve outcomes in breast cancer?
    Dimitrios H Roukos
    Angelos M Kappas
    Nature Clinical Practice Oncology, 2005, 2 : 342 - 343
  • [29] Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma: Does Drug Selection, Duration, or Sequence Affect Outcomes?
    Javed, A.
    Burkhart, R.
    Ronnekleiv-Kelly, S.
    Hasanain, A.
    Rosati, L. M.
    He, J.
    Makary, M.
    Laheru, D. A.
    Hruban, R. H.
    Zheng, L.
    Herman, J. M.
    Cameron, J.
    Wolfgang, C.
    Weiss, M.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S105 - S105
  • [30] Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Mazouni, Chafika
    Peintinger, Florentia
    Shu, Wan-Kau
    Andre, Fabrice
    Gonzalez-Angulo, Ana M.
    Symmans, W. Fraser
    Meric-Bernstam, Funda
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2650 - 2655
12345